AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32570252
Drug: AJM300 (α4-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 (α4-specific small molecule)
Trial: 32570252
Drug: PF-00547659 (antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00547659 (antibody against endothelial MadCAM-1)
Trial: 32570252
Drug: Ozanimod (S1PR1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanimod (S1PR1 and S1PR5 inhibitor)
Trial: 34968730
Drug: Dose-escalated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated group (initially 15 mg QD, escalated to 30 mg QD if lost response)
Trial: 34968730
Drug: Dose-escalated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated group
Trial: 33876196
Drug: Choline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline (500 mg/d)
Trial: 36302173
Drug: Cediranib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (30 mg)
Trial: 34851253
Drug: Medicine journals
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine journals (median impact factor 25.0)
Trial: 34851253
Drug: Medicine papers
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine papers
Trial: 33239018
Drug: Cases (received
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases (received HIV prevention services and enrolled in a 12‐month simulated vaccine efficacy trial using Hepatitis B vaccine)
Trial: 36154509
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD2) (5 mg/ml)
Trial: 36154509
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD1) (2 mg/ml)
Trial: 32271467
Drug: 1-mL PRGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mL PRGF injections
Trial: 32271467
Drug: 1-mL lidocaine
RxNorm normalized name: 0.1 ML Lidocaine Hydrochloride 1 % Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mL lidocaine injections
Trial: 36263928
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 U/ml (IDeg-100)
Trial: 34637858
Drug: Midazolam (0.0125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.0125 mg.kg-1)
Trial: 34637858
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo solution)
Trial: 34549720
Drug: HFNC oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFNC oxygen therapy
Trial: 34549720
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula oxygen therapy
Trial: 33871015
Drug: Daily motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily motivational text messages
Trial: 32017373
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no manipulation of IOL orientation)
Trial: 34558847
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 650 mg twice per day (1.3 g/day) for 4 days, followed by 650 mg on the morning of day 5.
Trial: 32299512
Drug: Brief psychiatric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychiatric treatment (10 sessions over 4 months)
Trial: 34907265
Drug: Ranibizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (2 mg/0.05 ml) administered via 3 intravitreal injections at approximately 30-day intervals
Trial: 36315274
Drug: Low dialysate
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dialysate sodium (135 mmol/L)
Trial: 36315274
Drug: Standard dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysate sodium (138 mmol/L)
Trial: 35099566
Drug: Continuously migrating
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously migrating TKAs (9 implants)
Trial: 36241349
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement treatment (HT)
Trial: 34157994
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (self-monitoring of daily steps plus counseling)
Trial: 32340904
Drug: Leucine-rich supplement
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine-rich supplement in combination with nutrition and physical exercise program
Trial: 34968819
Drug: Early oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oxytocin infusion following amniotomy
Trial: 34968819
Drug: Delayed oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed oxytocin infusion following amniotomy
Trial: 32646638
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker prescribed at discharge
Trial: 32646638
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy prescribed
Trial: 32375905
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg d-cycloserine (DCS)
Trial: 35560310
Drug: Cocoa-based flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa-based flavanols (FLV; 900 mg/d)
Trial: 33900204
Drug: Internet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based intervention for CVD management including medication and CVD risk data from EHR, personalized risk score estimation, goal setting, self-monitoring, social forum, heart health messages.
Trial: 35927020
Drug: Disadvantage indices
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disadvantage indices for vaccine allocation
Trial: 32643966
Drug: Other nonsteroidal
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other nonsteroidal anti-inflammatory drugs
Trial: 36380117
Drug: Soccer League
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soccer League (SL) intervention with 778 men attending soccer three times weekly for 6 months (72 sessions; 94% uptake, 45.5% weekly attendance rate) combined with an HIV/substance use cognitive-behavioral intervention.
Trial: 36380117
Drug: Control Condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Condition (CC) with 415 men receiving educational materials and referrals at 3 month intervals.
Trial: 32409944
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without bevacizumab (Non-BEV)
Trial: 32409944
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) treatment in first order recurrence
Trial: 32409944
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without bevacizumab (Non-BEV) in first order recurrence
Trial: 32409944
Drug: Bevacizumab (BEV)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (BEV) treatment in second or higher order recurrence
Trial: 32409944
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without bevacizumab (Non-BEV) in second or higher order recurrence
Trial: 33932804
Drug: Sardine group
RxNorm normalized name: sardine allergenic extract
DrugBank: European pilchard (DB10622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sardine group (SG) - 200 g of sardine per week
Trial: 32601978
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (participants recalled other recently consumed foods to increase salience of dietary variety)
Trial: 35843287
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids + 2 L of polyethylene glycol (PEG) 12 hours before CE (Arm B)
Trial: 35843287
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids + 1 L PEG + sodium ascorbate 3 hours before CE (Arm C)
Trial: 32140989
Drug: Short-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotic therapy (≤ 10 days)
Trial: 32140989
Drug: Long-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course antibiotic therapy (28 days)
Trial: 33040829
Drug: Guizhi Fuling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guizhi Fuling Pills (L, M, H groups)
Trial: 36304175
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral saline administration (5 mL·kg−1 of normal saline 2 hours before anesthesia)
Trial: 616774896
Drug: Vestibular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vestibular electrical stimulation (VES) combined with medical treatment; 30 min long, twice a day, three times a week, for 12 sessions at 80 Hz TENS.
Trial: 616774896
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (control group).
Trial: 35901339
Drug: Curcumin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (800 mg twice daily)
Trial: 616062932
Drug: Eicosapentaenoic (EPA)
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic (EPA) and docosahexaenoic (DHA) polyunsaturated fatty acids supplementation (2.4g/d, 1.6 g EPA and 0.8 g DHA, ratio 2:1)
Trial: 33865303
Drug: LDC cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDC cream (3% Defensil®, 5% dexpanthenol and ceramide)
Trial: 33865303
Drug: LDC cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDC cream
Trial: 35535242
Drug: Ultrasound-guided QLB
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided QLB with 20 ml of 0.375% ropivacaine
Trial: 36373323
Drug: NIR light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR light treatment (1060-1080 nm and 800-820 nm) for 12 weeks
Trial: 36027980
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical activity
Trial: 32498216
Drug: Difensil Immuno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difensil Immuno (DI) 10 mL for 90 days
Trial: 32498216
Drug: Difensil Immuno
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difensil Immuno (DI) 15 mL for 45 days
Trial: 32475902
Drug: Repaglinide-based combination
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide-based combination therapy with alogliptin
Trial: 32475902
Drug: Miglitol-based combination
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol-based combination therapy with alogliptin
Trial: 32475902
Drug: Miglitol monotherapy
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol monotherapy
Trial: 32475902
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with alogliptin
Trial: 33769243
Drug: ZnCl2 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnCl2 (1.5 µg/ml)
Trial: 33769243
Drug: Na2SeO3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na2SeO3 (5 µg/l)
Trial: 33769243
Drug: ZnCl2 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnCl2 + Na2SeO3 (1.5 µg/ml + 5 µg/l)
Trial: 35747142
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Engerix‐B, 20 μg/time) administered subcutaneously/intramuscularly at weeks 0, 4, and 24
Trial: 35747142
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Engerix‐B)
Trial: 35468736
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 9 weeks
Trial: 32533295
Drug: Internet-Delivered Parent-Child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-Delivered Parent-Child Interaction Therapy (iPCIT)
Trial: 32533295
Drug: Standard, clinic-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, clinic-based Parent-Child Interaction Therapy (PCIT)
Trial: 36274681
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix derivative administration
Trial: 34959861
Drug: Combination (BOTH)
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (BOTH)
Trial: 35732969
Drug: Juvenile Drug
RxNorm normalized name: CUNNINGHAM CLAMP,JUVENILE,BARD #004052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juvenile Drug Treatment Courts (JDTC)
Trial: 35164524
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus antipsychotics (Li+AP) (N = 50, primarily quetiapine and aripiprazole)
Trial: 35164524
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus anticonvulsants (Li+AC) (N = 107, primarily lamotrigine and valproate)
Trial: 35164524
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus antipsychotics and anticonvulsants (Li+AP+AC) (N = 73)
Trial: 35164524
Drug: Lithium plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium plus antipsychotics (Li+AP)
Trial: 32044039
Drug: Motor Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor Learning (ML) Group
Trial: 35383052
Drug: HIV/TB syndemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV/TB syndemic impact on attitudes towards TB treatment
Trial: 32290852
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day synbiotic (Familact) for 12 weeks
Trial: 35422467
Drug: Lamotrigine (pre-treatment)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (pre-treatment)
Trial: 32555927
Drug: Levosimendan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12 µg/kg bolus)
Trial: 34965784
Drug: Resourcefulness intervention
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resourcefulness intervention (teaching on social and personal resourcefulness skills, access to intervention video, skill application video-vignettes, four weeks of skills reinforcement using daily logs, four weekly phone contacts, booster sessions at two- and four-month postenrollment)
Trial: 33734306
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (2 mg) quarterly for 24 months
Trial: 33734306
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection quarterly for 24 months
Trial: 32501541
Drug: IM doravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM doravirine 200 mg (Treatment A: 1×1 mL, 20% suspension)
Trial: 32501541
Drug: IM doravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM doravirine 300 mg (Treatment B: 1×0.66 mL, 30% suspension)
Trial: 32501541
Drug: IM doravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM doravirine 200 mg (Treatment C: 2×0.5 mL, 20% suspension)
Trial: 32501541
Drug: Oral doravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doravirine
Trial: 35627562
Drug: Marine therapy
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine therapy group (MTG)
Trial: 616759071
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta‐TCP and rhGDF‐5 (400 mug)
Trial: 616759071
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta‐TCP and rhGDF‐5 (800 mug)
Trial: 35660485
Drug: Algorithm-based FiO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-based FiO2 titration with electronic medical record-based automated alerts
Trial: 35660485
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice FiO2 titration
Trial: 33388697
Drug: Routine speech
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine speech therapy (Control)
Trial: 33507315
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided quadratus lumborum block (QLB) using 0.5 mL/kg body weight 0.25% bupivacaine preoperatively
Trial: 32506135
Drug: Potassium supplementation
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplementation (3 g/d)
Trial: 32506135
Drug: Sodium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium supplementation (3 g/d)
Trial: 32053816
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CEUS) performed 48 hours after treatment
Trial: 32053816
Drug: CEUS responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CEUS responders (48 h after treatment)
Trial: 35896969
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron therapy and exercise training
Trial: 34275501
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral vitamin D3 drops (3‐12 months: 2000 IU; >12 months‐5y: 4000 IU; n=33) for 12 weeks
Trial: 34275501
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral depot dose of vitamin D3 granules (3‐12 months: 60,000 IU; >12 months‐5y: 150,000 IU; n=33) for 12 weeks
Trial: 35007624
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneous every 4 weeks
Trial: 32460885
Drug: NHS Speech
RxNorm normalized name: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHS Speech and Language Therapy (SLT)
Trial: 32460885
Drug: Lee Silverman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lee Silverman Voice Treatment (LSVT LOUD®)
Trial: 34846593
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (E) - chest drain removal at 5 ml/kg daily output
Trial: 34846593
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) - chest drain removal at less than 250 ml/day
Trial: 33225492
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment (all groups)
Trial: 33271536
Drug: Active learning
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active learning program (90-min sessions weekly for 24 weeks)
Trial: 35045362
Drug: V591 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V591 (low dose, 1 × 10^5 TCID50)
Trial: 35045362
Drug: V591 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V591 (high dose, 1 × 10^6 TCID50)
Trial: 35045362
Drug: V591 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V591 (two injections)
Trial: 35045362
Drug: V591 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V591 (low dose, two injections)
Trial: 35045362
Drug: V591 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V591 (high dose, two injections)
Trial: 36420365
Drug: Functional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional and Kinetic Treatment with Rehabilitation (FAKTR) combined with cryotherapy